Advertisement
Advertisement
U.S. Markets open in 4 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.94-0.48 (-3.58%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.42
Open13.42
Bid12.92 x 800
Ask16.00 x 1100
Day's Range12.77 - 13.43
52 Week Range12.20 - 20.75
Volume69,769
Avg. Volume65,185
Market Cap387.977M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-0.36
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 15, 2021
1y Target EstN/A
  • GlobeNewswire

    XBiotech to Launch Novel Candidate Therapy for Stroke

    Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today its plan to commence a randomized, placebo-controlled clinical study to test its new True Human™ antibody therapy for reducing brain injury after stroke. The study will be conducted across the United States at leading medical centers that provide advanced stroke care. During a stroke,

  • Simply Wall St.

    XBiotech's (NASDAQ:XBIT) investors will be pleased with their fantastic 514% return over the last three years

    We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...

  • GlobeNewswire

    Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

    AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix™, to be used in combination with cytotoxic anti-cancer agents. Natrunix™ specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of health

Advertisement
Advertisement